Who are Durvalumab plus chemotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AVELUMAB, DURVALUMAB, PD-1 / PD-L1 monoclonal antibody, Cisplatin / Carboplatin，Gemcitabine，Cindilimab, AB, Pf-06835375.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/durvalumab-plus-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Durvalumab plus chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab plus chemotherapy (Durvalumab plus chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor plus chemotherapy combination. Area: Oncology.

phase 3 PD-L1 inhibitor plus chemotherapy combination PD-L1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Durvalumab plus chemotherapy (Durvalumab plus chemotherapy) — AstraZeneca. Durvalumab blocks PD-L1 to restore anti-tumor immunity, while chemotherapy directly kills cancer cells and enhances immune activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Durvalumab plus chemotherapy TARGET	Durvalumab plus chemotherapy	AstraZeneca	phase 3	PD-L1 inhibitor plus chemotherapy combination	PD-L1
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
PD-1 / PD-L1 monoclonal antibody	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
AB	AB	GlaxoSmithKline	marketed	PD-L1 inhibitor	PD-L1
Pf-06835375	pf-06835375	Pfizer	marketed	Immunotherapy	PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor plus chemotherapy combination class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Durvalumab plus chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/durvalumab-plus-chemotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab